|
1
|
Keane C, Hamad N, Barraclough A, Lee YY, Talaulikar D, Ku M, Wight J, Tatarczuch M, Swain F, Gregory GP. Diagnosis and management of primary central nervous system lymphoma: a Consensus Practice Statement from the Australasian Lymphoma Alliance. Intern Med J 2021; 52:1624-1632. [PMID: 34927329 DOI: 10.1111/imj.15658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2021] [Revised: 10/24/2021] [Accepted: 12/05/2021] [Indexed: 11/28/2022]
Abstract
Primary central nervous system lymphoma is a clinicopathological disease entity that accounts for 1 % of all non-Hodgkin lymphoma (NHL). Advanced patient age, adverse disease biology and complexities of diagnosis and treatment render outcomes markedly inferior to systemic NHL. Despite this, an increasing evidence base including limited randomised controlled clinical trial data is informing optimal therapeutic strategies with methotrexate-based induction chemotherapy schedules and intensified consolidation in selected patients. This practice statement represents an evidence-based review of the literature and has been devised to assist healthcare professionals in the diagnosis and management of this disease. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- C Keane
- Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Australia.,University of Queensland, Brisbane, Australia
| | - N Hamad
- Department of Haematology, St Vincent's Hospital Sydney, Australia.,School of Medicine, Sydney, University of Notre Dame, Australia.,St Vincent's Clinical School, Sydney, University of New South, UK
| | - A Barraclough
- Department of Haematology, Fiona Stanley Hospital, Western Australia, Australia
| | - Y Y Lee
- Radiation Oncology, Division of Cancer Services, Princess Alexandra Hospital, Queensland, Australia
| | - D Talaulikar
- Department of Haematology, Canberra Hospital, ACT, Australia
| | - M Ku
- Department of Clinical Haematology, St Vincent's Hospital Melbourne, Fitzroy, Australia.,University of Melbourne, Victoria, Australia
| | - J Wight
- Department of Haematology, Townsville Hospital, Australia
| | - M Tatarczuch
- Monash Haematology, Monash Health, Clayton, Australia.,School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia
| | - F Swain
- Division of Cancer Services, Princess Alexandra Hospital, Australia
| | - G P Gregory
- Monash Haematology, Monash Health, Clayton, Australia.,School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia
| |
Collapse
|
|
2
|
Swain F, Daly J, Baidya S, Wilson B, Morrison J, Liew Y‐W, Powley T, Jivan Y, Bryant S, Allen A, Crampton N. Acute haemolytic reaction secondary to an ABO minor mismatched platelet transfusion from a group A blood donor. Transfus Med 2019; 29:133-135. [DOI: 10.1111/tme.12591] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2018] [Revised: 01/18/2019] [Accepted: 02/12/2019] [Indexed: 12/23/2022]
Affiliation(s)
- F. Swain
- Princess Alexandra Hospital Brisbane Queensland Australia
| | - J. Daly
- Australian Red Cross Blood Service Brisbane Queensland Australia
| | - S. Baidya
- Australian Red Cross Blood Service Brisbane Queensland Australia
| | - B. Wilson
- Australian Red Cross Blood Service Brisbane Queensland Australia
| | - J. Morrison
- Australian Red Cross Blood Service Brisbane Queensland Australia
| | - Y. ‐W. Liew
- Australian Red Cross Blood Service Brisbane Queensland Australia
| | - T. Powley
- Australian Red Cross Blood Service Brisbane Queensland Australia
| | - Y. Jivan
- QML Pathology Brisbane Queensland Australia
| | - S. Bryant
- Australian Red Cross Blood Service Brisbane Queensland Australia
| | - A. Allen
- Australian Red Cross Blood Service Brisbane Queensland Australia
| | | |
Collapse
|
|
3
|
Swain F, Baidya S, Casey J, Francis R, Pahn G, Burton M, Hassell P, Havelberg K, Jones G, Mahon D, Holdsworth R. Thrombocytopenia secondary to passive transfer of anti-HPA 1a antibodies from male donor plasma. Transfus Med 2018; 28:398-399. [PMID: 29873421 DOI: 10.1111/tme.12542] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Revised: 03/19/2018] [Accepted: 05/09/2018] [Indexed: 11/29/2022]
Affiliation(s)
- F Swain
- Pathology Queensland, Central Laboratory, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | - S Baidya
- Australian Red Cross Blood Service, Brisbane, Australia
| | - J Casey
- The Townsville Hospital, Douglas, Australia
| | - R Francis
- Princess Alexandra Hospital, Brisbane, Australia
| | - G Pahn
- Australian Red Cross Blood Service, Brisbane, Australia
| | - M Burton
- Australian Red Cross Blood Service, Brisbane, Australia
| | - P Hassell
- Australian Red Cross Blood Service, Brisbane, Australia
| | - K Havelberg
- Australian Red Cross Blood Service, Brisbane, Australia
| | - G Jones
- Australian Red Cross Blood Service, Brisbane, Australia
| | - D Mahon
- Australian Red Cross Blood Service, Brisbane, Australia
| | - R Holdsworth
- Australian Red Cross Blood Service, Brisbane, Australia
| |
Collapse
|
|
6
|
Fry L, Leonard JN, Swain F, Tucker WF, Haffenden G, Ring N, McMinn RM. Long term follow-up of dermatitis herpetiformis with and without dietary gluten withdrawal. Br J Dermatol 1982; 107:631-40. [PMID: 7171483 DOI: 10.1111/j.1365-2133.1982.tb00520.x] [Citation(s) in RCA: 87] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Seventy-eight patients with dermatitis herpetiformis have been followed up for periods ranging from 3 to 14 years (mean 7.4). Forty-two patients were treated with gluten-free diet (GFD) and thirty-six took a normal diet (ND). Thirty of the forty-two (71%) taking the GFD were able to discontinue drugs previously needed to control their rash compared with five (14%) of the thirty-six patients taking a ND. The mean time taken to reduce drug requirements for patients taking a GFD was 8 months (range 4-30), and for stopping drugs, 29 months (range 6-108). The incidence of macroscopic abnormality of the small intestine decreased from 69 to 15%, and the mean intra-epithelial lymphocyte count decreased significantly in those patients taking a GFD, whereas there was no significant change in patients taking a ND. The improvement in the skin and intestinal lesions was related to the strictness of the GFD.
Collapse
|
|
7
|
Abstract
Eleven patients with dermatitis herpetiformis, all requiring dapsone to control their rash and taking a normal diet, were given disodium cromoglycate (DSCG) 1.5-1.6 g daily. Eight out of the eleven patients continued to take DSCG for periods varying from 6-11 months, the other three patients chose to discontinue the DSCG before 6 months. Of the eight patients taking DSCG for at least 6 months, none was able to stop taking dapsone. In three of the eight, the dapsone requirements were unaltered, whilst in two it decreased and in three it increased. The mean daily dose of dapsone was 105 mg/day before DSCG and 141 mg/day after DSCG. In the eight patients who took DSCG for at least 6 months, intestinal biopsies were performed before and after this drug. The macroscopic appearance was unchanged in four, improved in two and worse in two. The mean interepithelial lymphocyte count was 346 before and 342 after DSG.
Collapse
|